AgingResearch.NewsJoin free

A-1331852

Intervention

1 paper2 findings

PubChem 71565985

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: National Science Foundation and 1 more
  • Cells1

Outcomes

2

Fibrosis

downin human cells1

1 study

  1. A-1331852 decreases fibrosis in human cells.

    “leading to a marked reduction in fibrosis, consistent with murine PSC and PBC models.”

    Cellsin 3D multilineage spheroids

    Development and Validation of a Scaffold-Free Human Multilineage Spheroid Model for Early Stage Cholangiopathies Driven by Cholangiocyte Senescence

    Liver international : official journal of the International Association for the Study of the Liver11 Sep 2025

Apoptosis

upin human cells1

1 study

  1. A-1331852 induces apoptosis in human cells.

    “Treatment with A-1331852 selectively induced apoptosis in senescent cholangiocytes and activated HSCs”

    Cellsin senescent cholangiocyte multilineage spheroids

    Development and Validation of a Scaffold-Free Human Multilineage Spheroid Model for Early Stage Cholangiopathies Driven by Cholangiocyte Senescence

    Liver international : official journal of the International Association for the Study of the Liver11 Sep 2025

More on Apoptosis

Latest

Related